VIRAL VECTOR SYSTEM FOR THE INTRODUCTION OF FOREIGN DNA EXPRESSION PRODUCTS INTO GALLINACEOUS BIRDS

Abstract: Viral vectors capable of delivering and expressing foreign DNA in gallinaceous birds are disclosed. These viral vectors also protect the birds against Marek's disease. Specifically, a herpesvirus of turkeys (HVT) vector is disclosed. Forwards and Backwards methods for the creation of these viral vectors are also disclosed.

Description: VIRAL VECTOR SYSTEM FOR THE INTRODUCTION OF FOREIGN DNA EXPRESSION PRODUCTS INTO GALLINACEOUS BIRDS AND METHODS FOR THEIR CREATION BACKGROUND OF THE INVENTION The present invention relates to a viral vector capa ble of delivering and expressing foreign genes in gallinaceous birds, particularly chickens. Specifically, this invention re lates to the use of the herpesvirus of turkeys (HVT) to delive and express foreign genes into gallinaceous birds and to induc immunity against Marek's disease. The herpesvirus of turkeys, particularly HVT strain FC126, is currently used in the poultry industry in vaccines t protect against the oncogeniσ Marek's disease virus (MDV). Virtually all broiler chicks are inoculated with HVT on day 1 after hatching. HVT is a naturally-occurring field virus iso¬ lated from turkeys and is not oncogenic for either chickens or turkeys. HVT normally induces viremia in chickens, and the re sponse peaks between 8-15 days after inoculation. Although there is evidence that a gradual decrease in the titer of HVT from inoculated birds occurs over time, 58% of the chickens in one study still had recoverable levels of HVT 76 weeks after vaccination as reported by Phillips and Biggs, J. Natl. Cancer Inst. 49_: 1367-1373, 1972. The persistence of this virus in the chicken makes i highly probable that products of exogenous genes which could b expressed during the infection would also be available to the host for a long period, possibly through harvest time for broilers. Thus, two reasons support the use of HVT as a viral vector. First, HVT is already widely used throughout the in¬ dustry to protect against Marek's disease. Second, HVT pro¬ vides a sound means for achieving a continuous supply of a non- viral gene product in poultry. SUMMARY OF THE INVENTION It is an object of the present invention to provide viral vectors capable of functioning as vaccines against Marek's disease which are also capable of introducing a func¬ tional gene of interest (GOI) into a gallinaceous bird. It is also an object of the present invention to provide methods for the construction of these viral vectors. Additional objects and advantages of the present invention will be set forth in part in the description which follows, or may be learned from practice of the invention. The objects and advantages may be realized and attained by means of the instrumentalities and combinations particularly pointed out in the appended claims. To achieve the objects and in accordance with the purposes of the present invention, a method for introducing a gene of interest into a gallinaceous bird is disclosed. This method comprises inserting the gene of interest into a non-essential region of a virus which is non-oncogenic in gallinaceous birds and is capable of being used as a vaccine against Marek's diseaase. Thus created, the viral vector is used to infect a gallinaceous bird, causing the gene of inter¬ est to be expressed. Two methods, the Backwards and Forwards methods, for creating these viral vectors are disclosed. In the Forwards method, a viral vector capable of introducing a functional gene of interest into a gallinaceous bird is created by: a. Locating a non-essential region in the genome of a virus which is non-oncogenic in a gallinaceous bird and which is a capable of being used as a vaccine against Marek's dis¬ ease; b. Inserting the gene of interest into the non-essential region of the viral genome to create a viral vector; and c. Infecting the gallinaceous bird with the viral vector. The Backwards method for the creation of a viral vector capable of introducing a functional gene of interest into a gallinaceous bird comprises: a. Identifying a viable virus which is non-oncogenic in a gallinaceous bird, which is capable of being used as a vaccine against Marek's disease, and which has a genomic defect which is manifested in an identifiable phenotype; b. Inserting the gene of interest coupled to a DNA sequence capable of repairing the viral defect into a non-essential region of the virus to create a viral vector; and c. Infecting the gallinaceous bird with the viral vector. It is understood that the foregoing general description in the following Detailed Description are exemplary and explan¬ atory only and are not restrictive of the invention as claimed. The accompanying drawings, which are incorporated in and con¬ stitute a part of this specification, illustrate one embodiment of the invention, and, together with the description, serve to explain the principles of the invention. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. Physical Map of the Region of DNA Encoding HVT TK. The location of Sail restriction endonuclease cleavage sites for EMBL3 phage clone Ell are indicated. Fragments are drawn approximately to scale, where the total length of the in¬ sert is about 21 kilobase pairs. The two end sites are from the vector, not from the HVT DNA insert. The 6.7 kb Sali frag¬ ment is expanded to show the location of the kan insertions that have been recovered in viral DNA. Insertions of sites 1-4 can be recovered following selection of HVT that grows in the presence of AraT (forward selection) . Insertions at sites 5-9 are found following rescue of the AraT 0 growth defect (Back¬ wards selection) . The exact locations of sites 1-6 are known from DNA sequence data, locations of sites 7-9 are from re¬ striction mapping. Sites are as follows: 1. Hpal, 2. Xbal, 3. Sspl, 4. Sspl, 5. Sspl, 6. Sspl, ' 7. Clal, 8. Nsil, 9 SnaBI. The region for which DNA sequence is presented (Figure 3) is indicated, and the expanded region shows the location of the two open reading frames. ORF 1 is believed to be the HVT thymidine kinase locus, also referred to in this application as locus X. Figure 2. The region of 11A that carries AraT resis¬ tance is probably TK. The 6.25 kb Sail fragment from 11A is shown, with an asymmetric EcoRI site that divides it into 2.0 and 4.25 kb segments. Indicated at the top is the segment of DNA that is required to restore wild-type phenotype to ATR β . Below are shown the endpoints of the various EMBL3 clones that SUBSTITUTESHEET contain all or part of 11A and the region of DNA that remains in a series of deletion mutants we have made in the original 11A subclone. Figure 3. DNA sequence of 2,720 base pairs in the region encoding HVT TK. Clones of both the large and small EcoRl-Sall subfragments were made in bacteriophage M13. In the small fragment, 2,026 base pairs, the DNA sequence from both strands was determined by cloning the fragment in both orienta¬ tions in M13mpl8 then creating a series of deletions from the sequencing primer site using the method of Henikoff (Gene 28, 351-359, 1984). 3' of the EcoRI site (Figure 1) DNA sequence has been generated using a series of primers to walk along a M13mpl9 subclone of hte 4.25 kb EcoRI-Sall subfragment described in Figure 2. Sequence has been determined using the dideoxy method (Sanger et al. , J. Mol. Biol. 143, 161-178, 1980). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT Reference will now be made to the preferred embodi¬ ments of the present invention. As noted above, the invention relates to the use of the described viral vectors in all gallinaceous birds. However, for the purposes of this discus¬ sion, chickens will be referred to as exemplary of gallinaceous birds. In addition, while HVT is described in detail herein as the presently preferred embodiment of the invention, use of other viruses as vectors are also contemplated. These other viruses include viruses (1) which are not oncogenic in the gallinaceous bird host; (2) which, contain at least one "nones ential" site into which foreign DNA can be inserted; and (3) which can be used as a vaccine for Marek's disease. Thus, the viruses encompassed within this invention include, but are not limited to HVT and any other virus which can protect against Marek's disease, such as Marek's disease virus (MDV) serotype 2 or MDV serotype 1, attenuated. Prior to a detailed discussion of this invention, definitions for certain terms used in the discussion should be established. "Nonessential" is intended to refer to a portion of the viral genome which is not necessary for virus propaga¬ tion. By "foreign DNA," it is intended to mean DNA which codes for a ene not naturall found in the viral vector. HVT contains a DNA genome of about 180 kilobase pairs (180 kbp) and has the potential for carrying a number of recombinant genes for delivery. Generally in order to express foreign genes in a viral vector and to ensure that the virus continues to grow, .the foreign genes must be inserted into re¬ gions of the viral genome that are nonessential for viral growth. The locus X, indicated on the map of a portion of the the HVT viral genome in Figure 1, was chosen as such a region because it was found to be nonessential for virus growth. While the present inventors believe that locus X is the thymidine-kinase locus, this has not yet been conclusively proven. However, for purposes of the discussion herein, the locus X depicted in Fig. 1 will be referred to as the thymidine-kinase (TK) locus. Other possibilities include some of the various glyσoprotein genes, believed to be nonessential because analo¬ gous proteins were found to be nonessential in the herpes sim¬ plex and pseudorabies viruses and especially the HVT protein A which is thought to be nonessential for growth and for protec¬ tion against Marek's Disease. In addition, the thymidine- kinase locus (TK) , if it is different from locus X, would also be a useful insertion site because TK has been shown to be nonessential in other large DNA viruses, including herpes sim¬ plex, pseudorabies and vaccinia viruses. Various foreign DNA molecules, also referred to here¬ in as "genes of interest" or "GOI," are contemplated for inser¬ tion into the viral vector. For example, antigens may be in¬ serted into " the vector and used to induce immunity to other fowl diseases. These antigens include, but are not limited to, antigens from other viruses, coccidia antigens and paramyosin, a muscle protein common to all invertebrate parasites, particu¬ larly shistosomes . In addition, analogs of somatostatin have been proposed for use in order to increase the fowl growth rate. Moreover, hormones such as growth promoters and immune regulators capable of growth stimulation or disease protection may be used. Assays for in vivo and in vitro expression of the genes of interest are contemplated. These include radioimmunoassays (RIAs) or enzyme linked immunosorbent assays (ELISAs) used for detecting foreign protein in cultured cells as well as in chicken serum. Also included are tests for in vivo IgA and IgG antibody levels to foreign proteins. Two general schemes are contemplated for the creation of the viral vectors of the present invention. The first, des¬ ignated herein as the "forward" scheme, involves the insertion of a GOI into a nonessential region of the viral genome. In a preferred embodiment of the present invention, this method is used to insert a GOI into the TK region of the genome. This results in a viral vector which exhibits an AraT resistant phenotype. In a second method of practicing the present inven¬ tion, hereinafter referred to as the "backwards" method, a virus which is viable but which has a genomic defect which is manifested in an identifiable manner is used. The GOI which is inserted into this defective or "crippled" virus is coupled with, a DNA sequence capable of repairing the viral defect. For example, in a virus which, has a defective TK region, and there¬ by exhibits AraT-resistance, the GOI is coupled with a DNA se¬ quence capable of restoring TK. Thus, restoration of TK, resulting in AraT sensitivity, is indicative of the insertion of the GOI into the viral vector. It should be noted that vi¬ ruses with defects in the TK gene generally grow more slowly than the wild-type virus. Thus, successful restoration of TK will result in a viral vector which has a growth advantage over the mutant strain. Although HVT has been widely used as a vaccine for Marek's disease since 1972, prior to the present invention HVT was virtually uncharacterized at the molecular and genetic lev¬ els. Thus, many tools and techniques had to be developed as prerequisites for the production of a recombinant HVT which could express a foreign gene. These included propagation of HV r preparation of viral DNA, preparation of cloned DNA li¬ braries of the HVT genome, preparation of infectious viral DNA for transfections, and development of a selection tool to use in identifying the desired viral recombinants. Success in each of these areas has enabled the inventors to define regions in the HVT viral DNA where the insertion of foreign DNA will not jeopardize the original function of HVT. The methods and means used to develop each of these prerequisites are described briefly below. These methods and means may be readily adapted, through use of the processes known to those of ordinary skill in the art applied in light of the teachings contained herein, to develop the tools necessary to develop the other viral vectors encompassed within the scope of the present invention. The following examples are designed to elucidate the teachings of the present invention and not to limit its scope. Various other modifications and equivalents of the examples will readily suggest themselves to those of ordinary skill in the art, particularly after issuance of this patent, without departing from the scope or spirit of the invention. EXAMPLES EXAMPLE 1 MOLECULAR AND GENETIC CHARACTERIZATION OF HVT AND DEFINITION OF TK REGION Primary cultures of chicken embryo fibroblasts (CEF) were prepared according to procedures described in Culture of Animal Cells by Freshney, R.I. (Alan R. Liss Inc., New York, 1983), specifically incorporated herein by reference, and were grown in medium M199 supplemented with bovine fetal serum. The cells were then infected with herpesvirus of turkeys (HVT) strain FC126 which is used in the industry to vaccinate poultry against Marek's disease. FC126 can be purchased from Salsbury Labs, Charles City, Iowa. When the cells exhibited approxi¬ mately 70% cytopathy, they were harvested and high molecular weight DNA was isolated according to procedures described by Maniatis et al ■ in Molecular Cloning (Cold Spring Harbor, New York), specifically incorporated herein by reference. HVT DNA represented about one to ten percent of total infected cell DNA. This HVT DNA was partially digested with restriction 3 endonuclease Sau3AI, and DNA fragments ranging from 15-20 X 10 base pairs in length were isolated according to the procedures described by Maniatis et al . , supra. The size selected DNA fragments were ligated to bacteriophage lambda vector EMBL3 which had previously been digested with the restriction endonuclease BamHI. The ligated DNA was packaged in vitro using commercially available packaging extracts obtained from Vector Cloning Systems (San Diego, California) according to the procedures described by the vendor. Packaged DNA was used to infect bacterial strain Q359 which was then plated on LB agar. DNA obtained from the resulting plaques was transferred to nitrocellulose filters and hybridized to 32 P labeled HVT DNA. ( 32 P labeled HVT DNA was obtained by nick-translation of electrophoretically purified HVT DNA in the presence of alpha 32PdCTP according to proce¬ dures described by Maniatis et al . , supra. Hybridization posi¬ tive plaques were picked. They constitute the HVT recombinant DNA library used in the subsequent experiments. The HVT recombinant DNA library consists of overlapping sequences of HVT DNA in bacteriophage lambda. High molecular weight DNA isolated from CEF infected with HVT was used to transfect uninfected CEF using the calcium phosphate precipitation technique described by Graham, F.L. and Van der Eb, A.J., Virology 52:456-467 (1973), specifically in¬ corporated herein by reference. Infectious virus was recovered four to five days after transfection. 1. Identification of the HVT TK Gene Insertion of foreign DNA into the HVT genome depends upon the relatively rare event of homologous recombination between infectious viral DNA and a plasmid carrying the gene of interest embedded within HVT sequences following co-trans ection of the two DNAs . Thus, some method had to be developed that would allow one to distinguish between the input infectious DNA and the desired recombinants in the inevitable mixed population of plaques resulting from co-transfection. 2. Locus X AraT Resistant Variant of TK~ a . Selection of an AraT Resistant Variant of HVT . It was demonstrated that CEF infected with HVT incor- porated significantly more 125I-deoxycytidine(125IdC) into DNA than mock-infected cells (Table 1). In HSV-infected cells, 125 IdC is incorporated into DNA only after it has been phosphorylated by the viral TK as described by Summers and Sum¬ mers, J. Virol. _24: 314-318 (1977), specifically incorporated herein by reference. Moreover, growth of HVT in CEF is inhib¬ ited by the drug AraT, whereas uninfected CEF appears to be un¬ affected. AraT (1-beta-D-arabinofuranosyl-thymine obtained from Calbiochem) is lethal to cells only once it is incorpo¬ rated into the DNA where it acts as a chain-terminator. Again by analogy to HSV, AraT-resistance is likely to be due to muta¬ tions in the thymidine kinase gene. TABLE 1 MOI cpm/mg protein CEF, uninfected n.a. 25,400 + HVT .001 37,500 + HVT .01 73,700 + HVT .02 103,200 + HVT .05 175,400 + HVT .1 202,000 + HVT .2 202, 500 + HVT .5 291,900 Vero, uninfected* n.a. 287,900 + HSV-1 .01 1, ,625,800 + HSV-1 .1 6 ' .108, 200 + HSV-1 .5 7, 093,200 Twelve-well plates were inoculated with cells 3 hours prior to infection. Cells were infected at varying multiplicities of infection (MOI) 125 I-iododeoxycytidine was added to the medium 2 hours post-infection at concentrations of 5 x 10 cpm/ml . The labeling period was 16 hours. Cells were harvested by precipitation on plates with cold 5% TCA (trichloroacetic acid) . Wells were washed 3 times with 5% TCA. Cell material was hydrolyzed in 0.5N NaOH, then aliquots were taken for counting and protein determination. *vero cells infected with HSV-1 are included for comparison. The sensitivity of wild-type HVT to AraT suggested that it may be feasible to identify the TK locus in HVT by se¬ lecting an AraT-resistant variant. 3. Isolation of AraT Resistant HVt AraT-resistant variants occur spontaneously in popu¬ lations of FC126, and are isolated by growing cell-free virus as described by Calnek et al. , Avian Dis . _16_: 52-56 (1972), spe¬ cifically incorporated herein by reference, in CEF in the pres¬ ence of 100 ug/ml AraT. Specifically, 150 mm tissue culture dishes are seeded with 2 X 10 cells of secondary CEF. Two hours later the medium is removed, and 2 X 10 pfu of cell-free HVT are adsorbed for 30 minutes. After adsorption, 30 ml of medium containing 100 ug/ml of AraT is added. Cells are fluid- changed every two days, always with AraT, and monolayers are screened for plaques 4-5 days post-infection at 40-fold magnfication using an inverted microscope. One AraT-resistant variant ATR" was found in 2 X 10 pfu screened initially. Sub¬ sequent experiments have yielded AraT resistant HVT at least that frequency. ATR° remains stable for at least nine passages in the absence of AraT. TABLE 2 Incorporation of 125 I-deoxycyti . dm . e ( ^ 3 IdC) in CEF cells infected with wild- type or ATR" HVT cpm/mg Protein Mock-infected 8, 622 Wild- type HVT 42 , 833 ATR 0 HVT 8, 807 — __ ATR° also fails to incorporate IdC into DNA (Table 2), as is expected for a TK~virus . The ability of ATR 0 to grow in culture in the pres¬ ence of FMAU (l-(2-fluoro-2-beta-D-arabinofuranoysl)-5-methyl- uracil) has been studied. This compound is commonly used as an anti-herpesvirus agent and is known to be specific for viral TK in the case of HSV. A TK~ recombinant was expected to grow in SUBSTITUTE SHEET -li¬ the presence of this drug while the drug would inhibit the growth of wild-type HVT. ATR° grows in FMAU, but less well than wild-type HVT in the absence of drug (Table 3). ATR 0 also grows more slowly than the wild-type virus in the absence of either AraT or FMAU. The reduced growth rate and virus yield of ATR 0 made it crucial to determine the ability of ART 0 to protect chickens against Marek's disease. A limited animal experiment was performed, the results from which are shown in Table 4. These results show that ATR 0 protects chickens against Marek's disease. Thus, it was deemed worthwhile to pursue the region of DNA that confers AraT resistance (Locus X, probably TK) as a site at which to insert foreign DNA. TABLE 3 Assay of wild-type HVT and ATR° on chick kidney cells* Virus FMAU Foci WT 0 + WT luM ATR° 0 • + ATR 0 luM + *Cell-free virus was inoculated onto chicken kidney cells in the presence or absence of FMAU. Agar overlays were applied one day post-infection, and plaques were scored 5 days post-infection. SUBST I TUTESHEET TABLE 4 Assay of ATR° in chickens for protection against Marek's disease Number of Birds with Marek's Disease 9 Weeks Post Challenge Genetically susceptible, pathogen-f ee, P2 chickens were vaccinated by subcutaneous injection of infected CEF. The wild-type (strain FC126) inoculum was 238 pfu/dose, and the ATR° inoculum was 3,400 pfu/dose. 10 days post-vaccination, challenge chicks were moved to a separate isolation unit and received n intraabdoininal injection of 500 pfu of cell-associated JM-10 strain (virulent Marek's dis¬ ease) virus Significant protection (p 0.001, chi square test) Several additional AraT-resistant mutants of HVT wer subsequently isolated. Three of these that have been tested also failed to incorporate 125IdC into DNA. These AraT- resistant mutants, like ATR°, seem to grow more slowly than wild-type HVT. The plaques are small and they consistently give lower titers. 4. Identification of the DNA Region Encoding the AraT-Resistance Phenotype All of the AraT resistant mutants are characterized by their ability to form plaques in the presence of AraT (whic completely inhibits the plaque-forming ability of wild-type HVT) and by their inability to incorporate 125I-deoxycytidine 125 ( IdC) into DNA. In addition, wild-type HVT has a growth advantage over the AraT-resistant variants. These differences between the wild-type HVT and HVT that are AraT-resistant, form the basis for a marker-rescue assay that allows for the identi¬ fication of the region of DNA, and thus the gene which confers resistance to AraT. DNA from the AraT resistant HVT (10 ug of total infected-cell DNA) is co-transfected with individual DNA clones (200 ng of plasmid DNA or 1 ug of phage DNA) repre¬ senting the genome of HVT. Two days after the DNA transfection, cells are switched from medium with 5% serum to medium with 2% serum. On day five, the transfected cells are split from their 60 mm dish to a 100 mm dish and 1 X 10 fresh secondary CEF are added. On day 8, monolayers are screened under the microscope for plaques and, when present, cell-free virus is made. 0.2 ml of the cell-free virus is adsorbed to fresh monolayers of CEF on 60 mm dishes. 40-45 hours post- infection the medium is replaced with 2 ml of 2% serum in M199 (Gibco) containing 1.36 uCi/ml of 125IdC (Amersham) . After 24 hours in the presence of 125IdC, cells and plaques are fixed in 50% methanol and stained with 0.4% crystal violet in 50% methanol . Plates are dried then autoradiographed. DNA from the clones containing the wild-type version of the AraT resis- tant region recombme with the infectious AraT Λ viral DNA and the resulting viruses are restored to wild-type growth, including the ability to incorporate 125IdC into DNA, a: sensitivity to Ara T . SUBST » TUT E SHEET The results of this assay as set forth in Table 5, unambiguously identified a 6.3kb Sail fragment from EMBL3 clone 11 as the piece of DNA which was altered in the AraT resistant mutants . Deletions in this piece of DNA have further charac¬ terized the location of the mutation to a 1000 base pair region of DNA within this fragment (Figures 2). SUBSTITUTESHEET TABLE 5 Marker rescue of ATR" by various DNAs 125 IdC Incorporati.on .nto Plaques EMBL3 Clones 117 119 20 118 121 113 11 13 108 112 + 114 + 116 + 123 53 106 105 110 Plasmids: 11A + delEl 2 + delHIO + delN9 + delN3 + delC14 + delS7 + delNH9 + delR2 These clones represent mapped HVT DNA. The positive phage clones share a region DNA as shown in Figure 2. 2 All of these plasmids contain deletions in 11A as indicated on the map in Figure 2. SUBSTITUTE SHEET 5. The DNA Sequence The DNA sequence of 2720 nucleotides has been deter¬ mined using standard dideoxy sequencing methods (Figure 3). The known sequence encompasses the 2 Kb Sail to EcoRI fragment (Figure 1) and continues an additional 69' mucleotides to the right of the EcoRI site. Analysis of this sequence using pro¬ grams purchased from International Biotechnologies, Inc. reveal two long open reading frames, the right-most of which (ORF 1, Figure 1) shows conservation between the derived protein se¬ quence and HSV as well as other thymidine kinase genes. Using similar search parameters, no homology between ORF 2 (left-most ORF, Figure 1) and HSV TK or other viral TK genes is detected nor is there detectable homology between ORF 1 and ORF 2 in the HVT sequence. The predicted a ino acid sequence of ORF 2, how¬ ever, does have significant homology to a predicted protein se¬ quence found in the analogous region of HSV-2 DNA. The func¬ tion of this HSV protein is unknown although mutations in this region cause reduced virus yields from HSV-1 infected cells. Based on the DNA sequence homologies and the genetic data which locate sequences imparting AraT-resistance and 125IdC incorpo¬ ration to the same region, we expect that ORF 1 is the thymidine kinase gene in HVT. EXAMPLE 2 INSERTION OF FOREIGN DNA INTO HVT USING THE "FORWARD" SELECTION PROTOCOL The 1.3 kb kanamycin gene (Kan) of TN 903 from pUC4K (obtained from Pharmacia) was inserted into 4 restriction endonuclease cleavage sites that lie within the TK open reading frame. These plasmids were individually co-transfected into CEF with infectious wild-type HVT DNA. Cultures were passed once to expand, then cell-free virus was adsorbed to fresh CEF and AraT was added to the medium following adsorbtion. Plaques growing in the presence of AraT were purified and expanded, and viral DNA was analyzed for insertion of Kan into HVT . Inser¬ tions at the four sites, an Hpal, Xbal and two Sspl sites (1-4 in Figure 1) yielded AraT resistant HVT. This demonstrates that it is possible to insert foreign DNA into this region of the HVT genome by using AraT resistance as the selection and TUTE SHEET purification mutants isolated to date have been found to grow less well than wild-type. In the case of the insertions at the Hpal, Xbal, and closest of the 2 Sspl sites (1-3 in Figure 1), it is believed that the Kan insertions affect another gene in addition to TK (0RF2). It appears that the expression of ORF 2 in these insertion mutants is reduced, and that this has a del¬ eterious effect on HVT virus production. EXAMPLE 3 INSERTION OF FOREIGN DNA INTO HVT USING THE BACKWARDS SELECTION SCHEME Insertion of the Kan gene from Tn903 that lie 3 ' of the coding region of HVT TK have been co-transfected with ATR" DNA. Because of the strong growth advantage of wild-type (WT) over AraT°, it is possible to use the accelerated growth in the recombinants as a selection tool. ' When the foreign DNA is linked to the rescuing DNA, it is possible to co-transduce the insertion of Kan, along with the rescue of AraT 0 , if the inser¬ tion of Kan does not affect the production of an adjacent, essential gene product. Six insertion sites for Kan that lie 3 ' of the termination codon defining the carboxy terminus of TK have been tried, 5 of these have resulted in the insertion of Kan as well as the repair of the AraT 0 growth defect (at sites 5-9 in Figure 1). These insertions span a one kb region of DNA that appears to be nonessential for normal HVT growth in CEF. In addition, they demonstrate that it is possible to recover HVT with foreign genes of interest using the Backwards selec¬ tion strategy where HVT with a defective TK is repaired by the introduction of DNA containing wild-type TK and adjacent for¬ eign DNA. This strategy can be extended to any nonessential site in the HVT genome by using infectious DNA from a virus - carrying a defective (preferably a big deletion to avoid later recombination) TK and a plasmid carrying good HVT TK gene and a gene of interest embedded within the nonessential HVT se¬ quences . EXAMPLE 4 EXPRESSION OF FOREIGN DNA IN HVT The HSV 1 TK gene carrying its own promoter ( the BamHI fragment from pHSV-106, BRL) was inserted into the Hpal site (site 1 in Figure 1) within the TK gene of HVT. This plasmid was co-transfected with ATR° DNA, and plaques with wild-type growth properties were isolated. DNA from these plaques show the expected pattern for insertion of the HSV TK gene into HVT. In this case, functional TK must be made from the HSV gene. It will be apparent to those skilled in the art that various modifications and variations can be made in the pro¬ cesses of the present invention. Thus, it is intended that the present invention cover these modifications and variations pro¬ vided they come within the scope of the appended claims and their equivalents. SUBS T ITUTESHEET

Claims: WHAT IS CLAIMED 1. A method for introducing a gene of interest into a gallinaceous bird comprising: (a) inserting the gene of interest into a non¬ essential region of a virus which is non-oncogenic in said bird and is capable of being used as a vaccine against Marek's disease to create a viral vector; (b) infecting a gallinaceous bird with the viral vectc .'; and (c) causing the gene of interest to be expressed. 2. The method of claim 1 wherein said gallinaceous bird is a chicken. 3. The method of claim 1 wherein said virus is se¬ lected from the group consisting of herpesvirus of turkeys (HVT); Marek's disease virus (MDV) serotype 2; and Marek's dis¬ ease virus (MDV) ser: ype 1, attenuated. 4. The method of claim 1 wherein the non-essential region is located with the gene encoding TK resistance. 5. The method of claim 1 wherein the non-essential region encodes a glycoprotein. 6. The method of claim 1 wherein the non-essential region is located within gene encoding Protein A. 7. The method of claim 1 wherein the non-essential region is located at a position of the genome between two DNA sequences encoding genes. 8. The method of claim 7 wherein the non-essential region is located 3' of the gene encoding AraT resistance. 9. The method of claim 1 wherein the gene of inter¬ est is selected from the group consisting of coccidia antigens. SUBSTITUTE s ^ " 10. A method for the creation of a viral vector capable of introducing a functional gene of interest into a gallinaceous bird comprising: (a) locating a non-essential region in the genome of a virus which is non-oncogenic in said bird and which is capable of being used as a vaccine against Marek's disease; (b) inserting the gene of interest into the non¬ essential region of the viral genome to create a viral vector; and (c) infecting a gallinaceous bird with the viral vector. 11. The method of claim 10 wherein the gene of in¬ terest is inserted into the TK region of the HVT virus . 12. A method for the creation of a viral vector capable of introducing a functional gene of interest into a gallinaceous bird comprising: (a) identifying a viable virus which is non- oncogenic in said bird, which is capable of being used as a vaccine against Marek's disease, and which has a genomic defect which is manifested in an identifiable manner; (b) inserting the gene of interest coupled to a DNA sequence capable of repairing the viral defect into a non-essential region of the virus to create a viral vector; and (c) infecting the gallinaceous bird with the viral vector. SUBSTITUTE SHEE

Inventors: BANDYOPADHYAY PRADIP, MARTIN SANDRA, BANDYOPADHYAY, PRADIP, MARTIN, SANDRA
Applicants: SYNERGEN INC, SYNERGEN, INC.
Application year: 1988
Main classification: C12N15
IPC codes: C12N15